BN Business News
Add your company to Business Communicator →

BUSINESS NEWS

Search Business News

Find articles by title or summary.

4/10/2025

Airworthiness Directives; Airbus Helicopters

The FAA is adopting a new airworthiness directive for Airbus Helicopters Model AS332C, AS332C1, AS332L, and AS332L1 helicopters to address the unsafe condition caused by the loss of tail rotor pitch control due to a fracture of the tail rotor slide.

4/9/2025

EPA Proposes Approval of Louisiana's Air Plan for 2010 SO2 NAAQS

The Environmental Protection Agency (EPA) is proposing to approve the portion of Louisiana's State Implementation Plan (SIP) demonstrating compliance with the 'good neighbor' provision of the Federal Clean Air Act for the 2010 1-hour sulfur dioxide (SO2) National Ambient Air Quality Standard (NAAQS).

4/9/2025

FDA Clears NASCOBAL Nasal Spray for Continued Sale

The FDA has determined that NASCOBAL cyanocobalamin nasal spray, 0.5 mg/spray, was not withdrawn from sale due to safety or effectiveness concerns, allowing it to continue being approved for use in abbreviated new drug applications.

4/9/2025

FDA Clears DECADRON for Sale, Ends Withdrawal Proceedings

The US Food and Drug Administration (FDA) has determined that DECADRON (dexamethasone sodium phosphate) solution/drops, equivalent to 0.1 percent phosphate, was not withdrawn from sale for reasons of safety or effectiveness. This decision means the FDA will not initiate procedures to withdraw approval of abbreviated new drug applications (ANDAs) for this product.

4/9/2025

FDA Extends Comment Period for Poppy Seed Industry Practices

The FDA is extending the comment period for a request for information on industry practices related to poppy seeds, including growing, harvesting, processing, and distribution, to gather more information on reducing opiate alkaloid content.

4/9/2025

FDA Clears Rimantadine Hydrochloride for Continued Use

The US Food and Drug Administration (FDA) has determined that FLUMADINE (rimantadine hydrochloride) 100mg tablets were not withdrawn from sale due to safety or effectiveness concerns, allowing the agency to continue approving Abbreviated New Drug Applications (ANDAs) for the product.

4/9/2025

FDA Clears Doxycycline Oral Suspension for Continued Approval

The FDA has determined that doxycycline oral suspension, 25mg/5mL, was not withdrawn from sale due to safety or effectiveness concerns. This decision allows the FDA to continue approving ANDAs for this product as long as they meet regulatory requirements.